MTOR and breast carcinoma: MCF-7 breast cancer cells with BRCA1 knockdown were more sensitive to pan-mTOR inhibitor PP242 and pan-PI3K/pan-mTOR inhibitor PKI-179 than cells with the non-targeting scrambled control (Figure 5A–C).